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Abstract Cushing’s disease is a severe clinical condition
caused by hypersecretion of corticosteroids due to exces-
sive ACTH secretion from a pituitary adenoma. This complex
endocrine disorder still represents a major challenge for the
physician in terms of efficient treatment. In the last years there
was only little progress in elucidating the molecular mecha-
nisms responsible for the constitutive and autonomous ACTH
secretion of pituitary corticotrophinomas. As a consequence,
no effective drug therapy is currently available, particularly if
surgical excision is not successful. In the present article we
examine recent studies that have investigated the therapeutic
potential of retinoic acid receptors as nuclear receptor targets
for the treatment of Cushing’s disease. Retinoic acid is an
efficient drug used for the treatment of different types of
cancers and it proved to act in animal models of Cushing’s
disease. The efficiency of this treatment in patients with this
disorder still needs to be tested in clinical trials.
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1 Pituitary adenomas and Cushing’s disease
Pituitary tumors are common neoplasms, reported to account
for 10–15% of all intracranial tumors, being therefore the
second most common neoplasm after meningeomas [1]. The
prevalence is 300/1,000,000 inhabitants. Pituitary adeno-
mas are composed of adenohypophysial cells and arise
usually in the sella turcica. Their hormonal activity is usually
reflective of the cytodifferentiation. The clinical picture can
be very variable, many tumors are silent and not frequently
diagnosed, while others may be life-threatening. Little is
known about the precise environmental and genetic factors
leading to their development, so preventive measures are
unavailable. About two-thirds of pituitary tumors express
and secrete pituitary hormones leading to various endocrine
syndromes. One of the most severe is the Cushing’s
syndrome, which results from chronic exposure to glucocorti-
coids in the blood from a variety of causes, including primary
pituitary adenoma (known as Cushing’s disease), primary
adrenal hyperplasia or neoplasia and ectopic ACTH pro-
duction (e.g., from a small cell lung cancer) [2–6]. It is
characterized by a typical abnormal fat deposition around the
neck, skin thinning, adrenal hyperplasia osteoporosis, insulin
resistance, dyslipidemia, myopathy, amenorrhea and hyper-
tension. Fatigue, irritation, anxiety and depression are also
common clinical features in these patients [2, 3, 5, 6]. At the
moment, there is no effective pharmacological therapy to
control ACTH over-secretion by pituitary tumors [2, 3, 5–8].
In the absence of efficient medical therapy, transsphenoidal
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adenomectomy is still the treatment of choice for ACTH-
secreting tumors [7, 8]. However, some difficulties prevent
this approach in many patients. In the first place, ACTH-
secreting pituitary adenomas are usually very small, although
they secrete abundant amounts of ACTH. Their small size
and structure makes it difficult to localize them with the
current imaging methods. This fact leads to a higher rate of
recurrence in these tumors due to partial resection. In some
cases, total hypophysectomy is needed to ensure the
resection of the tumor. In these cases a side effect of surgery
is the insufficiency of pituitary hormones. These patients
require constant monitoring of the endocrine axis and
hormone replacement therapy. Beside that, surgery is
associated, with significant post-operative morbidities [9,
10]. In case of adrenal tumor or ectopic ACTH secretion,
surgical removal of the tumor is mandatory, when possible.
Future studies are needed, on one hand to provide tools for a
better prediction of tumor behaviour and on the other to
provide novel targets for pharmaceutical therapy.
Only very recently, molecular biology studies have
provided novel potential targets for therapy. The role and the
ability of nuclear receptors such as retinoic acid receptors to
regulate normal and pathological pituitary tumor hormone
secretion and cell growth will be discussed.
2 Retinoic acid receptors
The retinoids are natural and synthetic derivatives of vitamin
A that regulate diverse cellular growth and differentiation
programmes, survival and death [11]. Retinoids activate the
transcription of target genes through interaction with the
nuclear transcription factors of the retinoic acid receptor
(RARα, RARβ, RARγ) and retinoid X receptor (RXRα,
RARβ, RXRγ) families [12–14]. The α, β and γ isoforms
are each expressed from the three isotypic genes (α, β and
γ), expressing by differential promoter usage and splicing
[15, 16]. At the molecular level, RARs and RXRs form
heterodimers that respond to RAR ligands. RXRs also
heterodimerize with other nuclear receptors, some of which
become transcriptionally active in the sole presence of an
RXR selective ligand (rexinoid) [11]. However rexinoid
agonists superactivate transcription induced by RAR-RXR
in the presence of RAR agonists. In the absence of ligand,
retinoid receptors bind specific retinoic-acid response
elements on target genes and recruit nuclear co-repressors,
such as NCOR (nuclear receptor co-repressor) and SMRT
(silencing mediator of RAR and thyroid hormone receptor).
Retinoid binding to these receptors leads to release of co-
repressors and recruitment of transcriptional co-activators
to regulate a diverse range of genes involved in transcrip-
tional and apoptosis regulation, proliferation and protein
modification [17].
Retinoic acid receptors are important drug targets for
cancer therapy and prevention [18, 19]. The activities
mediated by the retinoid receptors encompass, for example,
the induction of cell-cycle regulators (cyclin-dependent
kinase inhibitor p21WAF1/CIP1), the repression of AP1 (the
Fos-Jun proto-oncogene product), and the induction of the
tumor-cell-selective apoptosis ligand TRAIL [19, 20].
Strong evidence indicates that the RA-inducible RARβ,
acts as a tumor suppressor [11, 20].
At pharmacological dosages, retinoids are used to treat
patients with acute promyelocytic leukaemia (APL), as well
as other malignant, pre-malignant and non-malignant
disorders. The efficacy of retinoids in suppressing tumor
development has been demonstrated in animal carcinogen-
esis models [21].
All-trans-retinoic acid (ATRA) and 9-cis retinoic acid (9-
cis-RA) are the most biologically active retinoic acid
isomers, whereas 13-cis-retinoic acid (13-cis-RA) is con-
sidered less active and may require isomerization to ATRA
in order to exert biologic function [22, 23]. Differences in
ATRA and 13-cis-RA metabolism and pharmacokinetics
have been reported in cancer patients [24–30]. ATRA is
rapidly cleared from plasma (plasma half-life <1 h) and
induces its own metabolism, which is a significant thera-
peutic obstacle. In contrast, 13-cis-RA is slowly cleared
from plasma (plasma half-life >13 h) and does not induce
its own metabolism. Different strategies to overcome self-
induced ATRA metabolism and thus improve therapeutic
efficacy were proposed in emphysema patients [31]. The
authors concluded that intermittent therapy with high-dose
ATRA produced the greatest ATRA exposure, but alterna-
tive approaches for limiting self-induced ATRA catabolism
should be sought. A recent study on pharmacokinetics of
ATRA in adults and children with acute promyelocytic
leukaemia shows that although its bioavailability is similar
in both age groups the incidence of CNS toxicity due to
ATRA is higher in children than in adults [32]. Unfortu-
nately, a key limitation of retinoid therapy is that concen-
trations required for anticancer actions cause several side
effects, including teratogenicity, mucocutaneous toxicity,
defects in liver function, conjunctivitis, mucositis and severe
photosensitivity. Rexinoids are, in general, much less toxic
[33].
The search for isotype-selective modulators [15, 34–36]
is pursued to first, reduce side effects associated with current
retinoid therapy; second, elicit more specific biological
responses, because the tissue distribution of retinoid recep-
tors isotypes is not uniform, third, better define the
physiological role of each retinoid receptor isotype in the
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control of certain biological phenomena such as prolifera-
tion, differentiation and apoptosis [15].
A summary on retinoids and rexinoids that are of clinical
importance or being evaluated in clinical trials is provided
in Tables 1 and 2 [11].
3 Signaling pathways and transcriptional regulation
of ACTH biosynthesis
CRH increases pro-opiomelanocortin (POMC) gene ex-
pression and stimulates adrenocorticotrophin (ACTH) syn-
thesis and secretion [37] through the interaction with the
CRH receptor type 1 (CRHR1) localized in corticotrophs
(Fig. 1). Activation of the CRHR1 results in Gs-mediated
stimulation of adenylate cyclase, leading to increased levels
of intracellular cyclic AMP (cAMP), and the activation of
protein kinase A (PKA) [38], which stimulates different
transcription factors [39–41]. Two Nur DNA binding sites
have been identified on the POMC promoter. The proximal
binding sequence named Nur77-binding response element
(NBRE) binds Nur 77 or Nurr1 monomers. The distal Nur
response element (NurRE), constituted of two everted
NBRE related sites, binds Nur77 homodimers or Nur77/
Nurr1 heterodimers and plays a dominant role in mediating
stimulation by CRH [42–44]. Upon stimulation with CRH,
the ERK pathway is activated in corticotrophs and this
activation is instrumental in the regulation of Nur77/Nurr 1
[38]. The expression of these nuclear receptors in ACTH-
secreting cells and also in the hypothalamus and adrenal
glands might make them useful therapeutic targets for drugs
which may aim to modulate the activity of the HPA axis.
CRH also induces transcriptional activity of activating
protein 1 (AP-1) and cAMP response element binding
protein (CREB), which have been proposed to be involved
in POMC transcription at the level of the AP-1 site located
in the first exon [40, 45]. Other hormones and neuro-
peptides [e.g. arginine vasopressin (AVP)] also modify
POMC transcription by acting on the second messengers,
cAMP and Ca++ (the calcium/calmodulin pathway). Upon
glucocorticoid receptor binding, glucocorticoids exert their
negative effect by binding on the glucocorticoid responding
element (GRE) situated on the POMC promoter and thus,
inhibiting ACTH synthesis.
4 Retinoic acid and Cushing’s disease
4.1 In vitro data: AtT-20 pituitary corticotroph tumor cells
and human corticotrophinomas
Consistent with previous studies of retinoid action in other
tumor models, in AtT-20 pituitary ACTH -secreting tumor
cells, retinoic acid inhibits ACTH secretion in vitro by
Table 1 Retinoids in clinical trials or approved for therapy—adapted from Altucci et al. [11]
Name (trade name/company) Phase/indication
Tretinoin Launched: acne, APL, warts
Phase II: brain, breast, renal cancers, SCLC, Kaposi’s sarcoma, Wilms’ tumor, malignant melanoma
Isotretinoin Launched: acne
Phase III: isotretinoin plus IFNα plus vitamin E in III or stage IV head and neck cancer
Phase III: high-grade glioma
Phase III: combination therapy with isotretinoin in neuroblastoma
Phase II:T-cell malignancies
Phase II: IFNα plus isotretinoin plus paclitaxel recurrent SCLC
Phase II combination chemotherapy in juvenile myelomonocytic leukaemia
Tazarotene Launched: acne, psoriasis, photodamage
R667 Phase II: emphysema
Abbreviations: APL, acute promyelocytic leukaemia; IFNα, interferon-α; SCLC, small-cell lung cancer
Table 2 Rexinoids in clinical trials or approved for therapy - adapted




Bexarotene Launched: cutaneous T-cell lymphoma
Phase III: NSCLC
Phase II (oral): breast, colorectal, prostate,
psoriasis, renal
Phase II (topical): actinic keratosis, alopecia
areata, atopic dermatitis, Kaposi’s sarcoma,
mycosis fungoides, psoriasis
UAB-30 Preclinical
NSCLC Non-small-cell lung cancer
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inhibiting the transcriptional activity of the transcription
factors AP1 and Nur on the POMC gene, which encodes
ACTH [46]. However, this inhibitory action of retinoic acid
seems to be restricted to ACTH-secreting tumor cells, since,
in rat normal pituitary cells, neither ACTH, prolactin nor
growth hormone are affected by the treatment, demonstrat-
ing a specific effect on tumor cells probably related to the
distinct differentiation degree of normal cells versus tumor
cells. COUP-TF1 (chicken ovalbumin upstream promoter-
transcription factor 1), an orphan receptor that belongs to
the steroid/thyroid hormone receptor superfamily, with a
hypothetical role in the differentiation of ACTH-secreting
cells [46–48],was described to inhibit the retinoic acid
response pathways [48–50]. In this direction, in normal
ACTH-secreting cells—the corticotrophs—COUP-TF1 was
expressed and cells remained unaffected by the retinoic acid
treatment. By contrast, in ACTH-secreting tumors, no
expression of COUP-TF1 was observed. Moreover, the
retinoic acid effects were blocked in AtT-20 cells trans-
fected with the COUP-TF1 expression vector.
Treatment of human corticotrophinomas in primary
culture with 10 nM retinoic acid resulted in the inhibition
of the ACTH production by six out of eight tumors. All
tumors tested responded to retinoic acid when a higher doses
(100 nM) was used. ACTH inhibition was also observed in
tumor cells with lung origin, demonstrating that the ACTH
biosynthesis is affected by retinoic acid in different tumor
types. Furthermore retinoic acid inhibits cell proliferation
and induces apoptosis in ACTH-secreting tumor cells [46].
AP-1 and Nur77 were described to mediate the antiproli-
ferative effects of retinoic acid [47, 51]. Nevertheless, due
to the fact that retinoic acid has pleiotropic effects, it cannot
be excluded the possibility that other pathways independent
of AP-1 or Nur77/Nurr1 could contribute to this effects.
Moreover, retinoic acid induces caspase-3 activity, a key
mediator of the proteolytic cascade leading to apoptosis,
and reduces cell viability. In adrenal cortex cells, retinoic
acid inhibited the forskolin induced—corticosterone pro-
duction and—cell proliferation [46].
Regarding to other pituitary adenomas, retinoic acid has
been shown to stimulate growth hormone in vitro in the
lacto-somatotropic tumor cell line GH3 and in human
somatotropic adenoma cells [52, 53]. Therefore, retinoic
acid would not represent a possibility for the treatment of
growth hormone secreting tumors.
4.2 In vivo data: experimental Cushing’s disease in nude
mice
The in vivo retinoic acid effects paralleled the in vitro
effects [46]. When athymic nude mice were inoculated with
corticotroph tumor cells, large subcutaneous corticotroph
tumors were developed, whereas no tumors were observed
in mice injected with retinoic acid treated cells, indicating
that the anti-proliferative effects of retinoic acid are also
effective in vivo. Thus, retinoic-acid inhibition of prolifer-
ation and apoptosis induction combined to reduce tumor
mass. Moreover, administration of retinoic acid to mice that
already had experimental ACTH-secreting tumors, resulted
in the inhibition of tumor growth. Plasma levels of ACTH
and cortisol were reduced in retinoic acid treated mice,
compared with vehicle. These hormonal inhibition together
with the reduction of tumor mass, resulted in the reversion
of adrenal hyperplasia and skin atrophy, both characteristic
symptoms of Cushing’s syndrome [46].
Thus, the retinoic acid effects combine in vivo to reverse
the endocrine alterations and symptoms observed in
experimental Cushing’s syndrome [46].
Fig. 1 Regulation of ACTH
biosynthesis. CRH binds to its
seven transmembrane receptor,
induces cAMP and intracellular
calcium, and subsequently acti-
vates several transcription factors
including Nur, CREB, c-fos and
JunB, which activate the POMC
promoter leading to ACTH
biosynthesis
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4.3 In vivo data: Cushing’s disease in dogs
Cushing’s disease is common in dogs and it is almost always
caused by an ACTH secreting pituitary tumor. Ketoconazole
is an established treatment for Cushing’s disease, both in
the human and in dogs [54], which operates by interfering
with steroid biosynthetic pathways. Although ketoconazole
controls the excessive glucocorticoid secretion in some
patients, it does not inhibit tumor growth. In vitro, ketocona-
zole was shown, to inhibit the cAMP synthesis, necessary for
ACTH stimulation. However, other pituitary hormones also
require cAMP signalling for their normal biosynthesis,
therefore ketaconazole would not specifically inhibit ACTH
[55–57] but other hormones as well. As in humans, no
effective medical therapy for the treatment of dogs with
Cushing’s disease is currently available. The up to date
established treatments for dogs with Cushing’s disease have
limited efficacy and serious side effects.
A randomised study using retinoic acid in dogs with
Cushing’s disease was performed [58]. Dogs were treated
with retinoic acid (n=22 dogs) or ketoconazole (n=20 dogs)
for a period of 180 days. Clinical signs, plasma ACTH and
α-MSH, the cortisol/creatinine (RC/C) urine ratio and
pituitary MRI were assessed and compared at different time
points [58]. In dogs, two convertase enzymes are involved
in processing the POMC gene products, one active in
anterior pituitary cells secreting ACTH, whereas the other
is located in the intermediate-lobe cells secreting α-MSH
[59]. Therefore not only ACTH but also α-MSH was
assessed. In the ketoconazole group there were no signif-
icant changes in ACTH or α-MSH at any time studied. In
contrast, there was a significant reduction in plasma ACTH
and α-MSH in the retinoic acid treated dogs along the time.
The differences between the treatment groups were statis-
tically significant at 120 and 180 days for ACTH and
120 days for α-MSH. Thus, the ACTH and α-MSH
reduction suggests that retinoic acid acts on both, the
anterior and the intermediate pituitary lobe probably at the
POMC transcription level. The RC/C ratio decreased
significantly in both groups from 120 days on. This
reduction was significantly different between the groups at
180 days. Pituitary adenoma size was also significantly
reduced at the end of retinoic acid treatment. Nevertheless,
no reduction was observed in the ketoconazole group.
The survival time after initiation of treatment was
significantly longer in the retinoid acid group compared
with the ketoconazole group. Moreover, in the ketoconazole
group, more than 50% of the animals died before completing
the treatment, usually from complications of the glucocorti-
coid excess [58].
Retinoic acid induced an improvement in almost all the
clinical signs monitored (return of oestrus, food intake, skin
appearance and hair loss). Weight was the only parameter
studied that did not show significant differences between
the groups. Nevertheless, there was a decline in mean body
weight in both groups.
Thus, retinoic acid treatment controls ACTH and cortisol
hyperactivity, and tumor size in dogs with ACTH secreting
tumors leading to resolution of the clinical phenotype. No
adverse events with retinoic acid were recorded, except for
one case of footpad hyperkeratosis. Moreover, there was no
evidence of hepatotoxicity during or after the study in terms
of hepatic enzyme abnormalities. Based on these data, the
dose of retinoic acid used was not only effective but also
appeared to be safe. Because of the similarity of canine to
many human diseases, it has been suggested that the dog
may help to bridge the gap between preclinical drug studies
and the effects of the same drug in humans [60]. This study
highlights the possibility of using retinoic acid as a novel
therapy in the treatment of ACTH-secreting tumors in
humans with Cushing’s disease [58]. It is important to note
that according to the “U.S. Food and Drug Administration
guidelines” for extrapolating animal doses to human equiv-
alent doses considering weight and skin surface, the retinoic
acid doses used in the above described mice [46] and dogs
[58] studies are within the range of doses that could be used
in humans.
4.4 BMP-4 involvement in the retinoic acid inhibitory action
During pituitary organogenesis, bone morphogenic protein
2 and 4 (BMP2 and 4), two members of the TGF-β
superfamily, have been shown to play an important para-
crine/autocrine role during the initial steps of the anterior
pituitary development [61]. BMP-4 is expressed in the
corticotrophs of human normal pituitary and its expression
is reduced in corticotrophinomas obtained from Cushing’s
patients compared to the normal pituitary. BMP-4 treatment
of AtT-20 mouse corticotrophinoma cells has an inhibitory
effect on ACTH secretion and cell proliferation. AtT-20
cells stably transfected with a dominant negative form of
the BMP-4 signal cotransducer Smad-4 or the BMP-4
inhibitor noggin have increased tumorigenicity in nude
mice, demonstrating that BMP-4 has an inhibitory role on
corticotroph tumorigenesis in-vivo. Retinoic acid induces
both BMP-4 transcription and expression and its antiproli-
ferative action is blocked in Smad-4 dominant negative and
noggin transfected Att-20 cells that do not respond to BMP-
4. Therefore, BMP-4 is induced by and mediates some of
the retinoic acid effects [62].
5 Conclusion
At present, there is no effective pharmacological therapy
that has been clinically tested to control ACTH-oversecretion
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by pituitary tumors. Recent advances in elucidating the
function of nuclear receptors have resulted in the develop-
ment of novel approaches. The potential importance of
retinoic acid receptors in the treatment of Cushing’s disease
was tested in different animal models with ACTH secreting
pituitary cells. Thus, the antiproliferative action and the
ACTH and corticosterone inhibition induced by retinoic acid
in vitro were confirmed in vivo in mice with experimental
ACTH secreting tumors and in dogs with Cushing’s disease.
6 Key unanswered questions
Retinoic acid might represent a potential therapeutic option
to inhibit ACTH production, as well as tumor growth in
Cushing’s disease. However, the efficiency of these treat-
ments in patients with Cushing’s syndrome still needs to be
tested in clinical trials.
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